Sukumar Nagendran - 30 Dec 2022 Form 4 Insider Report for Taysha Gene Therapies, Inc. (TSHA)

Role
President and Head of R&D, Director
Signature
/s/ Kamran Alam, Attorney-in-Fact
Issuer symbol
TSHA
Transactions as of
30 Dec 2022
Transactions value $
$0
Form type
4
Filing time
04 Jan 2023, 15:51:02 UTC
Previous filing
15 Dec 2022
Next filing
18 May 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TSHA Stock Option (right to buy) Award $0 +790K $0.00 790K 30 Dec 2022 Common Stock 790K $2.26 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the total number of shares underlying the option shall vest and become exercisable on December 16, 2023 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.